Clinical Trial Update: Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial update covers the combination of epirubicin and docetaxel for metastatic prostate cancer, with the study status shown as terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Prostate Cancer | Phase 1 | Status: TERMINATED